Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Intervention With Decitabine/Cedazuridine in High-Risk CCUS
NCT06802146Phase 1Recruiting
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inqovi in clonal cytopenia of undetermined significance (CCUS) (2 cohorts). Primary endpoint: Feasibility Failure Rate. Started Feb 2025; status: recruiting.
02
Drugs
inqovi
03
Conditions
clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on NCT06802146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802146.